# Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease

> **NCT02519036** · PHASE1,PHASE2 · COMPLETED · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 46 (actual)

## Conditions studied

- Huntington's Disease

## Interventions

- **DRUG:** ISIS 443139 10 mg
- **DRUG:** ISIS 443139 30 mg
- **DRUG:** ISIS 443139 60 mg
- **DRUG:** ISIS 443139 90 mg
- **DRUG:** ISIS 443139 120 mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02519036
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-06
- **Primary completion:** 2017-11-08
- **Final completion:** 2017-11-08
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2019-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02519036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02519036, "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02519036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*